酒石酸唑吡坦的安全风险及使用要点

杨玉慧, 许秀丽, 朱珠

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (14) : 1188-1193.

PDF(1080 KB)
中国药学杂志
PDF(1080 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (14) : 1188-1193. DOI: 10.11669/cpj.2019.14.012
论著

酒石酸唑吡坦的安全风险及使用要点

  • 杨玉慧, 许秀丽, 朱珠*
作者信息 +

The Drug Safety and Rational Use of Zolpidem Tartrate

  • YANG Yu-hui, XU Xiu-li, ZHU Zhu*
Author information +
文章历史 +

摘要

目的 针对酒石酸唑吡坦的用药剂量、用药时间、注意事项等给出安全建议。方法 检索相关网站和数据库,对酒石酸唑吡坦的药学特点、临床应用情况、不良反应、药物相互作用及合理使用进行概述。结果 为保障患者用药安全,建议女性及65岁及以上的老年人宜使用最低有效剂量5 mg·d-1;尽量短期使用,服药疗程不宜超过4周;失眠患者可选择按需治疗(间断性、非每夜给药);严格遵医嘱,按照规定的疗程和剂量服用。结论 酒石酸唑吡坦可治疗多种类型的失眠,疗效确切,不良反应较轻。临床医生与药师需重视唑吡坦用药安全风险,告知患者使用禁忌和注意事项。

Abstract

OBJECTIVE To givesafety recommendations for the dose, time of administration, and precautions for zolpidem tartrate. METHODS Search relevant websites and databases, the pharmaceutical characteristics, clinical application, adverse reactions, drug interactions and rational use of zolpidem tartrate were reviewed. RESULTS In order to ensure the safety of medication for patients, it is recommended that women and the elderly aged 65 years and above should use the minimum effective dose of 5 mg·d-1. Short-term use, the course of medication should not exceed 4 weeks. Insomnia patients can choose to treat as needed (intermittent, not every night). Follow the prescribed course of treatment and dosage in strict accordance with the doctor's advice. CONCLUSIONS Zolpidem tartrate can treat various types of insomnia with definite curative effect and mild adverse reactions.Clinicians and pharmacists should pay attention to the safety risks of zolpidem and inform patients of the contraindications and precautions.

关键词

酒石酸唑吡坦 / 用药风险 / 安全警示 / 合理用药

Key words

zolpidem tartrate / medication risk / safety warning / rational drug use

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
杨玉慧, 许秀丽, 朱珠. 酒石酸唑吡坦的安全风险及使用要点[J]. 中国药学杂志, 2019, 54(14): 1188-1193 https://doi.org/10.11669/cpj.2019.14.012
YANG Yu-hui, XU Xiu-li, ZHU Zhu. The Drug Safety and Rational Use of Zolpidem Tartrate[J]. Chinese Pharmaceutical Journal, 2019, 54(14): 1188-1193 https://doi.org/10.11669/cpj.2019.14.012
中图分类号： R969.3   

参考文献

[1] APHA. Riskey use of zolpidem still common [EB/OL] .FDA,2018(2018-9-28)[2018-12-05] . https://www.pharmacist.com/article/risky-use-zolpidem-still-common.
[2] MOORE T J, MATTISON D R. Assessment of patterns of potentially unsafe use of zolpidem[J] . JAMA Internal Med, 2018, 178(9):1275-1277.
[3] LI Y, ZENG X T, ZHENG J B. Review of the clinical application of zolpidem in China[J] . Shanghai Med Pharm J(上海医药), 2015,(11):26-28.
[4] FDA. AMBIEN CR label [EB/OL] . FDA, 2005(2018-9-18)[2018-12-05] . https://www. accessdata. fda. gov/drugsatfda_docs/label/2018/021774s023lbl. pdf.
[5] FDA. TOVALT ODT label [EB/OL] . FDA, 2007(2007-5-1)[2018-12-05] . https://www. accessdata. fda. gov/drugsatfda_docs/label/2007/021412lbl. pdf.
[6] FDA. AMBIEN label [EB/OL] . FDA, 2007(2018-9-18)[2018-12-05] . https://www. accessdata. fda. gov/drugsatfda_docs/label/2018/019908s042lbl.pdf.
[7] FDA. ZOLPIMIST label [EB/OL] . FDA, 2009(2009-1-6)[2018-12-05] . https://www. accessdata. fda. gov/drugsatfda_docs/label/2018/019908s042lbl.pdf.
[8] FDA. EDLUAR label. [EB/OL] . FDA, 2009(2018-10-26)[2018-12-05] . https://www. accessdata. fda. gov/drugsatfda_docs/label/2018/019908s042lbl. pdf.
[9] HARRISON T S, KEATING G M. Zolpidem: a review of its use in the management of insomnia[J] . CNS Drugs, 2005, 19: 65-89.
[10] DROVER D R. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone[J] . Clin Pharmacokinet, 2004, 43(4):227-238.
[11] FDA. Ambien (zolpidem tartrate) [EB/OL] . FDA, 2007(2007-2-16)[2018-12-05] . https://wayback. archive-it. org/7993/20170112170201/http://www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150812. htm.
[12] FDA. Ambien, Ambien CR (zolpidem tartrate) [EB/OL] . FDA, 2007(2007-3-14)[2018-12-05] . https://wayback. archive-it. org/7993/20170112170202/http://www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150813. htm.
[13] FDA. Drug Safety Communication [EB/OL] . FDA, 2013(2013-1-10)[2018-12-05] . https://wayback. archive-it. org/7993/20170404172106/https://www. fda. gov/Drugs/DrugSafety/ucm334033. htm.
[14] FDA. Zolpidem Containing Products [EB/OL] . FDA, 2013(2013-5-14)[2018-12-05] . https://wayback. archive-it. org/7993/20170406045039/https://www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738. htm.
[15] FDA. FDA Drug Safety Communication [EB/OL] . FDA, 2016(2016-8-31)[2018-12-05] . http://www. fda. gov/Drugs/DrugSafety/ucm518473. htm.
[16] CFDA. Notification of the inclusion of 4 drugs such as zolpidem in the mangement of psychotropic substances [EB/OL] . CFDA, 2001(2001-5-19)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL0844/10688. html.
[17] CFDA. Pharmacovigilance newsletter, Issue 1, 2018(Total Issue 50) [EB/OL] . CFDA, 2008(2008-1-28)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1990/28306. html.
[18] CFDA. Adverse Drug Reaction Information Bulletin (28th issue) alert to abnormal sleep behavior caused by sedative hypnotics[EB/OL] . CFDA, 2010(2010-5-24)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1989/49155. html.
[19] CFDA. Notice on revision of the sedative hypnotic instruction [EB/OL] . CFDA, 2010(2010-9-1)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1706/53831. html.
[20] CFDA. Pharmacovigilance Newsletter, Issue 7, 2012 (Total Issue 111)[EB/OL] . CFDA, 2012(2012-7-27)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1990/74517. html.
[21] CFDA. Pharmacovigilance Newsletter, Issue 2, 2013 (Total Issue 118)[EB/OL] . CFDA, 2013(2013-2-28)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1990/81215. html.
[22] CFDA. Pharmacovigilance Newsletter, Issue 6, 2013 (Total Issue 122)[EB/OL] . CFDA, 2013(2013-6-28)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1990/96334. html.
[23] CFDA. Announcement of China Food and Drug Administration on Amending the Instructions for Oral Formulation of Zolpidem Tartrate (No. 89 of 2015)[EB/OL] . CFDA, 2015(2015-7-8)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1706/124104. html.
[24] CFDA. Drug Alert News, 2016, Issue 9 (Total Issue 161)[EB/OL] . CFDA, 2016(2016-10-18)[2019-1-2] . http://samr. cfda. gov. cn/WS01/CL1990/165382. html.
[25] LI Y, ZHOU F X, CHEN J F. Causes of insomnia and related factors[J] . Chin J Gerontol(中国老年学), 2009, 29(1):115-117.
[26] KOSHOREK G, ROEHRS T, SICKLESTEEL J, et al. Dose effects of zolpidem on transient insomnia[J] . Sleep Res, 1988, 17: 47.
[27] UCHIMURA N, NAKAJIMA T, HAYASH K, et al. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam[J] . Prog Neuro-Psychopharmacol Biol Psychiatry, 2006, 30(1):22-29.
[28] ERMAN M K, ZAMMIT G, RUBENS R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia[J] . J Clin Sleep Med, 2008, 4(3):229-234.
[29] KRYSTAL A D, ERMAN M, ZAMMIT G K, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study[J] . Sleep, 2008, 31(1):79-90.
[30] ERMAN M, GUIRAUD A, JOISH V N, et al. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial[J] . Sleep, 2008, 31(10):1371-1378.
[31] ZHANG L L, ZHANG S I. Therapeutic effect of zolpidem tartrate on insomnia after acute stroke[J] . Strait Pharm J(海峡药学), 2012, 24(2):199-200
[32] FAVA M, ASNIS G M, SHRIVASTAVA R K, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial[J] . J Clin Psychiatry, 2011, 72(7):914-928.
[33] REN B. A clinical controlled study of zolpidem and estazolam in the treatment of insomnia[J] . The Med Forum(基层药学论坛), 2018, 22(17):2348-2349.
[34] XU Q. Cost-effectiveness comparison of zolpidem tartrate and alprazolam in the treatment of insomnia[J] . Chin Pharm(中国药业), 2018, 27(5):90-92.
[35] ERMAN M K. Therapeutic options in the treatment of insomnia[J] . J Clin Psychiatry, 2005, 66(suppl 9): 18-23.
[36] LI Q W, LI L J. Clinical study of zolpidem on the treatment of post-stroke insomnia[J] . Sichuan Med J(四川医学), 2007(6):610-612.
[37] GAO L S, ZHANG S Q. Clinical study of zolpidem on the treatment of insomnia[J] . J Pract Ner Dis(实用神经疾病杂志), 2005(1):14-15.
[38] American Geriatrics Society 2015 Beers Criteria Update Expert Panel, Fick D M, Semla T P, et al. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults[J] . J Am Geriatrics Society, 2015, 63(11):2227-2246.
[39] FDA. Ambien (zolpidem tartrate) [EB/OL] FDA,2009(2007-3-31)[2018-12-05] . https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019908s022lbl.pdf.
[40] FDA. Edluar (zolpidem tartrate sublingual tablets) [EB/OL] FDA, 2009 (2009-3-26)[2018-12-05] . https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021997lbl.pdf.
[41] FDA. Zolpimist (zolpidem tartrate) Oral Spray [EB/OL] FDA, 2009,(2009-1-6)[2018-12-05] . https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022196lbl.pdf.
[42] MACFARLANE J, MORIN C M, MONTPLAISIR J. Hypnotics in insomnia: the experience of zolpidem[J] . Clin Ther, 2014, 36(11):1676-1701.
[43] BUSCEMI N, VANDERMEER B, FRIESEN C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a Meta-analysis of RCTs[J] . J General Internal Med, 2007, 22(9):1335.
[44] HAMPTON L M, DAUBRESSE M, CHANG H Y, et al. Emergency department visits by adults for psychiatric medication adverse events[J] . JAMA Psychiatry, 2014, 71(9):1006-1014.
[45] DOLDER C R, NELSON M H. Hypnosedative-induced complex behaviours: incidence, mechanisms and management[J] . Cns Drugs, 2008, 22(12):1021.
[46] HWANG T J, NI H C, CHEN H C, et al. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study[J] . J Clin Psychiatry, 2010, 71(10):1331-1335.
[47] CAO Y T, LI Z Z, ZHANG Y F, et al. Sleep walking induced byzolpidem[J] . Adv Drug React J(药物不良反应杂志), 2007(4):279-280.
[48] ZHANG Q Y, WANG X Q, RUAN L M, et al. Zolpidem causes hallucination 1 case[J] . Chin J Drug Depend(中国药物依赖性杂志), 2015, 24(1):78.
[49] U.S. FOOD AND DRUG ADMINISTRATION.Risk of next morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist)[EB/OL] . 2013, [2019-01-18] .https://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf.
[50] ZANG R H, YU R. Hallucination caused by combined zolpidem tartrate and venlafaxine[J] . Adv Drug React J(药物不良反应杂志), 2010, 12(2):143-144.
PDF(1080 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉